Skip to main content
Log in

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes

  • Report on Investigational Drugs
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Glucagon-like peptide-1 (GLP-1) is the main member of the incretin family and stimulates insulin secretion by binding with its specific receptor on pancreatic β-cells. In addition, GLP-1 exerts broad beneficial effects on the glucose regulation by suppressing food intake and delaying stomach emptying. Now, long acting GLP-1 analogs including exenatide and liraglutide have been approved for the treatment of diabetes mellitus type 2, however long-term injection can limit their use for these chronic patients. In this report, the authors provide a review on the development of non-peptide GLP-1 receptor agonists and introduce a novel agonist DA-15864.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abu-Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., and Elahi, D., The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab., 94, 1843–1852 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Baggio, L. L. and Drucker, D. J., Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 2131–2157 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., Xie, X., Nan, F., Young, A. A., and Wang, M. W., A nonpeptidic agonist of glucagonlike peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. U. S. A., 104, 943–948 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Dong, M., Gao, M., Pinon, D. I., and Miker, L. J., Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol. Endocrinol., 22, 1489–1499 (2008).

    Article  PubMed  CAS  Google Scholar 

  • Hoare, S. R. J., Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov. Today, 10, 417–427 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Kim, M. K., Kim, H. D., Cheong, Y. H., Yang, E. K., Choi, S. H., Shin, C. Y., Jung, H. H., Kim, E. J., Moon, H. S., Yang, H. S., and Son, M. H., Orally active small molecule GLP-1R agonist, DA-15864 increases insulin secretion in mice. 70 th Scientific Sessions of Annual Meeting of American Diabetes Association, Jun 25–29, 2010, Orlando, FL; Poster presentation (590-P).

  • Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M., D., de Jong, J. C., Jorgensen, A. S., Kercher, T., Kostrowicki, J., Madsen, P., Olesen, P. H., Petersen, J. S., Poulsen, F., Sidelmann, U. G., Sturis, J., Truesdale, L., May, J., and Lau, J., Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U. S. A., 104, 937–942 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Kwon, D. Y., Kim, Y. S., Ahn, I. S., Kim, D. S., Kang, S., Hong, S. M., and Park, S. M., Exendin-4 potentiates insulinotropic action partly via increasing β-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J. Pharmacol. Sci., 111, 361–371 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Lin, F. and Wang, R., Molecular modeling of the threedimensional structure of GLP-1R and its interactions with several agonists. J. Mol. Model., 15, 53–65 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Lovshin, J. A. and Drucker, D. J., Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol., 5, 262–269 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Phillippe, J. and Raccah, D., Treating type 2 diabetes: How safe are current therapeutic agents? Int. J. Clin. Pract., 63, 321–332 (2009).

    Article  Google Scholar 

  • Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Julia, X. C., Cao, J. X. C., Cox, A. L., Michael, M. D., Sanfeliciano, S. M. G., Tebbe, M. J., and Coghlan, M. J., Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human Islets. Diabetes, 59, 3099–3107 (2010).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Moon-Ho Son.

Additional information

Edited by Mi-Kyoung Kwak, College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Korea Tel: 82-53-810-2823, E-mail: mkwak@ynu.ac.kr

Moon-Ho Son Director, Drug Discovery Research Laboratories, Dong-A Pharm. Co., LTD. Main Research Area

Antidiabetic agent: DPP4 inhibitor, non-peptide GPCR agonist Antiobesity agent

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moon, HS., Kim, MK. & Son, MH. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. Arch. Pharm. Res. 34, 1041–1043 (2011). https://doi.org/10.1007/s12272-011-0721-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-011-0721-z

Keywords

Navigation